New German guidelines
|
|
- Dora Bradley
- 5 years ago
- Views:
Transcription
1 CAPNETZ-Symposium: Community-acquired pneumoniae New German guidelines S3-Guideline of PEG, DGP, DGI and CAPNETZ Höffken G 1, Lorenz J 2, Kern W 3, Welte T 4, Bauer T, Dahlhoff C, Dietrich E, Ewig S, Gastmeier P, Grabein B, Halle E, Kolditz M, Marre R, Sitter H. Paul-Ehrlich-Society for Chemotherapy 1, German Society for Pneumology 2, German Society for Infectiology 3, Competence-Network CAPNETZ Germany 4, Association of the Scientific Medical Societies in Germany
2 German CAP guideline S3-guideline acc. to the Association of the Scientific Medical Societies in Germany AWMF Consensus finding Evidence-based medicine Formulation of clinical algorythms Decision analysis Outcome analysis (in preparation with Competence network CAPNETZ, Federal Agency for Quality Control BQS) All mayor scientific societies incorporated No financing by pharmaceutical companies
3 Classification of evidence (Centre of Evidence Based Medicine 1999) Recommendation Evidence Description A B 1a 1b 1c 2a 2b 2c 3a 3b Evidence by systematic review of sound RCT Evidence by one appropriate RCT Anything-or nothing principle Evidence by systematic review of cohrit studies Evidence by one cohort study /RCT intermediate quality Evidence by outcome-research-studie Evidence by systematic review of case-control-studies Evidence by one case-control-study C 4 Evidence by case series/cohort studies and casecontrol studies of intermediate quality D 5 Expert opinion, laboratory results
4 Targets and target groups Targets Standards for diagnosis and therapy of LRTI Rational prescription of antimcrobials To reduce not indicated usage To avoid the extensive usage of specific antibiotic classes To avoid the emergence of resistant strains Critical review of microbiologic diagnostics Risk stratification Risk-adapted antimicrobial therapy Best clinical outcome and cost effectiveness
5 Principle structure of the guideline on community-acquired pneumonia and lower respiratory tract infections
6 Risk stratification
7 CAPNETZ Mortality figures according different scoring systems CURB CRB CRB-65 Mortality (%) Number positive criteria CAPNETZ 2005
8 Validation of matsr Prediction of mortality Rule Sensitivity Specifity PPW NPW matsr 94% 93% 49% 99,5% mbtsr 51% 80% 16% 96% Ewig S et al. Thorax 2004
9 Decision making for risk stratification Outpatient at the GP CRB-65: one positive criterion: consider hospital admission Inpatient at the emergency room mats score: If positive: consider ICU admission mats negative: CURB B If 1 positive criteria: consider ICU admission B
10 Diagnostics microbiological tests
11 Blood cultures (%) Blood culture + Change of Tx PSI 1 PSI 2 PSI 3 PSI 4 PSI 5 Waterer GW et al. Resp Med 2001; 95: 78 Outpatient setting: No blood cultures B Hospital: Optional blood cultures in mild to moderate CAP Mandatory blood cultures in the ICU B B
12 Sputum Accuracy and practicability in CAP Culture positive sputum 10/116 (9%) Culture guided therapy - all 1/116 (1%) - microscopic valide sputum 1/23 (4%) False positive rate of purulent sputum 14/19 (74%) Ewig Chest 2002; 121: 1486 Outpatient setting: no sputum testing A Hospital setting: sputum testing, if quality criteria fulfilled B
13 Serology and antigen testing No recommendation M. pneumoniae serology C. pneumoniae serology For all amplification assays Pneumococcal antigen test (to be revisited) Procalcitonin i.s. (to be revisited) Recommendation for antigen testing Legionella antigen-test in urine (2c) B B
14 Modifying factors for defining subgroups with different spectra of pathogens
15 CAP-spectrum of causative pathogens Lit. Höffken et al. Chemotherapie-Journal 2005; 14 mild moderate severe S. pneumoniae 38 (30-49) 27 (15-48) 28 (20-31) M. pneumoniae 8 (ng 13) 5 (2-9) 2 (0 3) H. influenzae 13 (4-22) 6 (0 7) 7 (0 10) C. pneumoniae 21 (0-32) 11 (0-17) 4 (0-7) S. aureus 2 (0-2) 3 (0-4) 9 (0-22) Enterobacteriaceae 0 4 (1-8) 9 (2-18) P. aeruginosa 1 3 (0-4) 4 (0-5) L. pneumophila 0 4 (0-8) 12 (0-23) Polymicrobial infection up to 27%, unknown aup to 50%
16 Dichotomy Mild outpatient CAP Risk (y/n) Comorbidities, advanced age, antibiotic pretreatment, recent medical contact Yes: Spectrum with less atypicals, more enterobacteria (2c) A Moderate and severe in-patient CAP Risk for P. aeruginosa (y/n) Pulmonary comorbidity, recent hospital discharge Yes: Spectrum with more enterobacteriaceae and P. aeruginosa (2c) A
17 Empirical treatment with ß- lactam-antibiotics and macrolides in the era of pneumococcal resistance
18 Actual resistance rates in Germany for pneumococci PEG statistics on resistance 2004 Penicillin G 1,2% ( 2 mg/l) Erythromycin DIN 11,3 % ( 8mg/l) CLSI 18,1% ( 1 mg/l) Doxycycline 8,2% No restriction to aminopencillines and macrolides in the empirical treatment of CAP B
19 A International Prospective Study of Pneumococcal Bacteremia: Correlation with In Vitro Resistance, Antibiotics Administered, and Clinical Outcome. YU VL et al. CID 2003; 37: 230
20 A International Prospective Study of Pneumococcal Bacteremia: Correlation with In Vitro Resistance, Antibiotics Administered, and Clinical Outcome. YU VL et al. CID 2003; 37: 230
21 Failure of Macrolide Antibiotic Treatment in Patients with Bacteremia Due to Erythromycin-Resistant Streptococcus pneumoniae John R. Lonks, 1 et al. CID 2002; 35: (24%) of 76 case patients and none of 136 matched controls were taking a macrolide when blood was obtained for culture (P = ). 5 (24%) of 21 case patients with the low-level resistant M phenotype and none of 40 controls were taking a macrolide (P =.00157).
22 ß-lactams versus macrolides any preferences in empiric therapy for mild to moderate CAP?
23 Clinical success Mild to moderate CAP n=6.749 Superiority for antibiotics with activity against atypicals Superiority for antibiotics without activity against atypicals
24 Outpatient therapy in mild CAP without risk factors A Compound Dosage (per d) Duration First choice Aminopenicilline - Amoxicillin 70 kg 3 x 1,0 g 7 10 d < 70 kg 3, 0,75 g Alternatives - Azithromycin 1 x 500 mg 3 d - Clarithomycin 2 x 0,5 3d / 0,25 g 7 10 d - Roxithromycin 1 x 300 mg 7 10 d oder - Doxycycline 1 x 200 mg / 100mg 7 10 d
25 Outpatient therapy in mild CAP with risk factors A Compound Dosage (per d) Duration First choice Aminopenicilline - Amoxicillin/ 70 kg 3 x 1,0 g 7 10 d clavulanate < 70 kg 2 x 1 g - Sultamicillin 3 x 0,75 g 7 10 d Alternatives - Levofloxacin 1 x 0,5 g 7 10 d - Moxifloxacin 1 x 0,4 g 7 10 d - Cefpodoxim- 2 x 0,2 g 7 10 d Proxetil - Cefuroxim-Axetil 2 x 0,5 g 7 10 d
26 Outpatient management of CAP recommendation A, evidence 4 Safe home care Clinical follow-up after h Stable oxygenation Stable hemodynamics Safe intake of medication In any suspicion: hospital admission
27 ß-lactam macrolide combination
28 Dual therapy including macrolides on mortality, LOS/charges Brown et al. Chest 2003; 123: 1503 Risk group C LOS (d) Death (%) Charges ($) Risk class D LOS (d) Death (%) Charges ($) ß-Lactam Mono ß-Lactam + macrolide n= ,38 7, n= , n= * 4,1* 8.601* n= ,24* 9.917
29 Not critically ill Baddour AJRCCM 2004
30 Critically ill Baddour AJRCCM 2004
31 Inpatient therapy in moderate CAP without risk factors for P. aeruginosa Compound Dosage (per d) Duration Aminopenicilline -- Amoxicillin/ clavulanate 3 x 2,2 g iv 7 10 d A -- Sultamicillin 3 x 3,0 g iv 7 10 d -- Cefuroxim-Axetil 3 x 1,5 g iv 7 10 d -- Ceftriaxone 1 x 2,0 g iv 7-10 d -- Cefotaxime 3 x 2,0 g iv 7-10 d -plus/minus Macrolide Fluoroquinolone -Levofloxacin 1 x 0,5 g iv 7 10 d -Moxifloxacin 1 x 0,4 g iv 7 10 d
32 Inpatient therapy in moderate CAP with risk factors for P. aeruginosa A Compound Dosage (per d) Duration Anti-pseudomonal ß-lactam -- Piperacillin/ Tazobactam 3 x 4,5 g iv 7 10 d -- Cefepime 3 x 2,0 g iv 7 10 d -- Imipenem 3 x 1,0 g iv 7 10 d -- Meropenem 1 x 1,0 g iv 7-10 d -- Cefotaxime 3 x 2,0 g iv 7-10 d -plus/minus Macrolide or Fluoroquinolone - Levofloxacin 2 x 0,5 g iv 7 10 d - Ciprofloxacin plus gram+ coverage 3 x 0,4 g iv 7 10 d
33 Combination therapy in patients with severe CAP
34 Mono- vs combination- ABT (ß-lactam plus/minus aminoglycoside) M Paul et al. BMJ 2004; 328: Same ß-Lactam clinical efficay any ß-Lactam tolerability
35 Combination Antimicrobial Therapy in P. aeruginosa Bacteremia inadequate empiric ABT adequate empiric Mono- ABT adequate empiric Combi- ABT Chamot E et l. AAC 2003; 2756
36 Inpatient therapy in severe CAP without risk factors for P. aeruginosa A Compound Dosage (per d) Duration Anti-pseudomonal ß-lactam -- Piperacillin/ Tazobactam 3 x 4,5 g iv 7 10 d -- Ceftriaxone 1 x 2,0 g iv 7 10 d -- Cefotaxime 3 x 2,0 g iv 7 10 d - plus Macrolide Alternative Fluoroquinolone - Levofloxacin 2 x 0,5 g iv 7 10 d - Moxifloaxin 1 x 0,4 g iv 7 10 d
37 Inpatient therapy in severe CAP with risk factors for P. aeruginosa A Compound Dosage (per d) Duration Anti-pseudomonal ß-lactam -- Piperacillin/ Tazobactam 3 x 4,5 g iv 7 10 d -- Cefepime 3 x 2,0 g iv 7 10 d -- Imipenem 3 x 1,0 g iv 7 10 d -- Meropenem 1 x 1,0 g iv 7-10 d - plus Macrolide or plus Fluoroquinolone - Levofloxacin 2 x 0,5 g iv 7 10 d - Ciprofloxacin 1 x 0,4 g iv 7 10 d
38 General recommendations for the treatment in hospital Initial parenteral therapy Exemption: flouroquinolones (1) Exemption: macrolides in combination (1) High dosage (4) Oral sequential therapy (1) Limited duration of therapy (2) 7-10 Tage Wasserfallen 2004; Dibar 2003; Vergis 2000
39 Summary Quality of management may be improved by evidence-based guidelines Crucial is a good mix of internal and external evidence Challenge: impementation of guideline Constant up-dating Individualise antibiotic treatment
40 Consensus Conference Invited Scientific Societies/Institutions Berufsverband der Allgemeinärzte Deutschlands Hausärzteverband (BDA) e.v. Berufsverband der Pneumologen e.v. (BDP) - Dachverband der Landesverbände der Pneumologen Deutschlands Berufsverband der Deutschen Internisten (BDI) e.v. Bundesministerium für Gesundheit und Soziale Sicherung (BMGS) Deutsche Gesellschaft für Allgemeinmedizin und Familienmedizin (DEGAM) e.v. Deutsche Gesellschaft für Hygiene und Mikrobiologie e.v. (DGHM) Deutsche Gesellschaft für Innere Medizin e.v. (DGIM) Deutsche Gesellschaft für Internistische Intensivmedizin und Notfallmedizin (DGIIN) e.v. Deutsche Interdisziplinäre Vereinigung für Intensiv- und Notfallmedizin (DIVI) e.v. Medizinischer Dienst der Spitzenverbände (MDS) Patientenliga Atemwegserkrankungen e.v.
National Clinical Guideline Centre Pneumonia Diagnosis and management of community- and hospital-acquired pneumonia in adults
National Clinical Guideline Centre Antibiotic classifications Pneumonia Diagnosis and management of community- and hospital-acquired pneumonia in adults Clinical guideline 191 Appendix N 3 December 2014
More informationMeasure Information Form
Release Notes: Measure Information Form Version 3.0b **NQF-ENDORSED VOLUNTARY CONSENSUS STANDARDS FOR HOSPITAL CARE** Measure Set: Pneumonia (PN) Performance Measure Identifier: Measure Information Form
More informationBai-Yi Chen MD. FCCP
Treatment strategies for hospitalized versus nonhospitalized CAP patients: Asian perspective Bai-Yi Chen MD. FCCP Professor of Medicine Division of Infectious Disease, Infection Control Team The First
More informationCommunity Acquired Pneumonia. Epidemiology: Acute Lower Respiratory Tract Infections. Community Acquired Pneumonia (CAP) Outline
Community Acquired Pneumonia (CAP) Outline Lisa G. Winston, MD University of California, San Francisco Zuckerberg San Francisco General Epidemiology Diagnosis Microbiology Risk stratification Treatment
More informationPneumonia considerations Galia Rahav Infectious diseases unit Sheba medical center
Pneumonia considerations 2017 Galia Rahav Infectious diseases unit Sheba medical center Sir William Osler (1849 1919) "Father of modern medicine Pneumonia: The old man's friend The captain of the men of
More informationNQF-ENDORSED VOLUNTARY CONSENSUS STANDARDS FOR HOSPITAL CARE. Measure Information Form
Last Updated: Version 3.2a NQF-ENDORSED VOLUNTARY CONSENSUS STANDARDS FOR HOSPITAL CARE Measure Set: Pneumonia (PN) Performance Measure Identifier: Measure Information Form Organization Set Measure ID#
More informationAppropriate antimicrobial therapy in HAP: What does this mean?
Appropriate antimicrobial therapy in HAP: What does this mean? Jaehee Lee, M.D. Kyungpook National University Hospital, Korea KNUH since 1907 Presentation outline Empiric antimicrobial choice: right spectrum,
More informationAntibiotic usage in nosocomial infections in hospitals. Dr. Birgit Ross Hospital Hygiene University Hospital Essen
Antibiotic usage in nosocomial infections in hospitals Dr. Birgit Ross Hospital Hygiene University Hospital Essen Infection control in healthcare settings - Isolation - Hand Hygiene - Environmental Hygiene
More informationGUIDELINES FOR THE MANAGEMENT OF COMMUNITY-ACQUIRED PNEUMONIA IN ADULTS
Version 3.1 GUIDELINES FOR THE MANAGEMENT OF COMMUNITY-ACQUIRED PNEUMONIA IN ADULTS Date ratified June 2008 Updated March 2009 Review date June 2010 Ratified by Authors Consultation Evidence base Changes
More informationGENERAL NOTES: 2016 site of infection type of organism location of the patient
GENERAL NOTES: This is a summary of the antibiotic sensitivity profile of clinical isolates recovered at AIIMS Bhopal Hospital during the year 2016. However, for organisms in which < 30 isolates were recovered
More informationAntibiotic Abyss. Discussion Points. MRSA Treatment Guidelines
Antibiotic Abyss Fredrick M. Abrahamian, D.O., FACEP, FIDSA Professor of Medicine UCLA School of Medicine Director of Education Department of Emergency Medicine Olive View-UCLA Medical Center Sylmar, California
More informationCommunity-Acquired Pneumonia. Community-Acquired Pneumonia. Community Acquired Pneumonia (CAP): definition
Community-Acquired Pneumonia Lisa G. Winston, MD University of California, San Francisco San Francisco General Hospital Community-Acquired Pneumonia Talk will focus on adults Guideline for healthy infants
More informationSuggestions for appropriate agents to include in routine antimicrobial susceptibility testing
Suggestions for appropriate agents to include in routine antimicrobial susceptibility testing These suggestions are intended to indicate minimum sets of agents to test routinely in a diagnostic laboratory
More informationGuidelines for the Initiation of Empirical Antibiotic therapy in Respiratory Disease (Adults)
Guidelines for the Initiation of Empirical Antibiotic therapy in Respiratory Disease (Adults) Community Acquired Pneumonia Community Acquired Pneumonia 1) Is it pneumonia? ie new symptoms and signs of
More informationGuidelines for the Initiation of Empirical Antibiotic therapy in Respiratory Disease (Adults)
Guidelines for the Initiation of Empirical Antibiotic therapy in Respiratory Disease (Adults) Community Acquired Community Acquired 1) Is it pneumonia? ie new symptoms and signs of a lower respiratory
More information2016 Antibiotic Susceptibility Report
Fairview Northland Medical Center and Elk River, Milaca, Princeton and Zimmerman Clinics 2016 Antibiotic Susceptibility Report GRAM-NEGATIVE ORGANISMS 2016 Gram-Negative Non-Urine The number of isolates
More informationControl emergence of drug-resistant. Reduce costs
...PRESENTATIONS... Guidelines for the Management of Community-Acquired Pneumonia Richard E. Chaisson, MD Presentation Summary Guidelines for the treatment of community-acquired pneumonia (CAP) have been
More informationManagement of Hospital-acquired Pneumonia
Management of Hospital-acquired Pneumonia Adel Alothman, MB, FRCPC, FACP Asst. Professor, COM, KSAU-HS Head, Infectious Diseases, Department of Medicine King Abdulaziz Medical City Riyadh Saudi Arabia
More informationAntibiotic Updates: Part II
Antibiotic Updates: Part II Fredrick M. Abrahamian, DO, FACEP, FIDSA Health Sciences Clinical Professor of Emergency Medicine David Geffen School of Medicine at UCLA Los Angeles, California Financial Disclosures
More informationAntibiotics in the Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease
Antibiotics in the Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease Sung Kyu Kim, M.D.Young Sam Kim, M.D. Department of Internal Medicine Yonsei University College of Medicine,
More information2017 SWAB Secretariat SWAB p/a Postbus ZG Bergen Lb Tel
Management of Community-Acquired Pneumonia in Adults: 2016 Guideline Update From The Dutch Working Party on Antibiotic Policy (SWAB) and Dutch Association of Chest Physicians (NVALT) Dr. W. J. Wiersinga
More informationa. 379 laboratories provided quantitative results, e.g (DD method) to 35.4% (MIC method) of all participants; see Table 2.
AND QUANTITATIVE PRECISION (SAMPLE UR-01, 2017) Background and Plan of Analysis Sample UR-01 (2017) was sent to API participants as a simulated urine culture for recognition of a significant pathogen colony
More information2015 Antibiotic Susceptibility Report
Citrobacter freundii Enterobacter aerogenes Enterobacter cloacae Escherichia coli Haemophilus influenzenza Klebsiella oxytoca Klebsiella pneumoniae Proteus mirabilis Pseudomonas aeruginosa Serratia marcescens
More informationPneumonia. Community Acquired Pneumonia (CAP): definition. At least 2 new symptoms
Pneumonia Lisa G. Winston, MD University of California, San Francisco San Francisco General Hospital Community Acquired Pneumonia (CAP): definition At least 2 new symptoms Fever or hypothermia Cough Rigors
More informationAntibiotic. Antibiotic Classes, Spectrum of Activity & Antibiotic Reporting
Antibiotic Antibiotic Classes, Spectrum of Activity & Antibiotic Reporting Any substance of natural, synthetic or semisynthetic origin which at low concentrations kills or inhibits the growth of bacteria
More informationEUCAST recommended strains for internal quality control
EUCAST recommended strains for internal quality control Escherichia coli Pseudomonas aeruginosa Staphylococcus aureus Enterococcus faecalis Streptococcus pneumoniae Haemophilus influenzae ATCC 59 ATCC
More informationESISTONO LE HCAP? Francesco Blasi. Sezione Medicina Respiratoria Dipartimento Toraco Polmonare e Cardiocircolatorio Università degli Studi di Milano
ESISTONO LE HCAP? Francesco Blasi Sezione Medicina Respiratoria Dipartimento Toraco Polmonare e Cardiocircolatorio Università degli Studi di Milano Community-acquired pneumonia (CAP): Management issues
More informationTreatment of Respiratory Tract Infections Prof. Mohammad Alhumayyd Dr. Aliah Alshanwani
Treatment of Respiratory Tract Infections Prof. Mohammad Alhumayyd Dr. Aliah Alshanwani 30-1-2018 1 Objectives of the lecture At the end of lecture, the students should be able to understand the following:
More informationCommunity Acquired Pneumonia: An Update on Guidelines
Community Acquired Pneumonia: An Update on Guidelines Claudia Summa, BScPhm Pharmacy Resident September 12, 2006 Objectives To give a brief description of the pathophysiology of community acquired pneumonia
More informationUpdated recommended treatment regimens for gonococcal infections and associated conditions United States, April 2007
Updated recommended treatment regimens for gonococcal infections and associated conditions United States, April 2007 1 Ongoing data from CDC 's Gonococcal Isolate Surveillance Project (GISP), including
More informationTreatment Duration for Uncomplicated Community-Acquired Pneumonia: The Evidence in Support of 5 Days
Treatment Duration for Uncomplicated Community-Acquired Pneumonia: The Evidence in Support of 5 Days Executive Summary National consensus guidelines created jointly by the Infectious Diseases Society of
More informationRational management of community acquired infections
Rational management of community acquired infections Dr Tanu Singhal MD, MSc Consultant Pediatrics and Infectious Disease Kokilaben Dhirubhai Ambani Hospital, Mumbai Why is rational management needed?
More informationجداول میکروارگانیسم های بیماریزای اولویت دار و آنتی بیوتیک های تعیین شده برای آزمایش تعیین حساسیت ضد میکروبی در برنامه مهار مقاومت میکروبی
جداول میکروارگانیسم های بیماریزای اولویت دار و آنتی بیوتیک های تعیین شده برای آزمایش تعیین حساسیت ضد میکروبی در برنامه مهار مقاومت میکروبی ویرایش دوم بر اساس ed., 2017 CLSI M100 27 th تابستان ۶۹۳۱ تهیه
More informationOptimising antibiotic policies in the Netherlands, part VIII. Revised SWAB Guidelines for antimicrobial therapy of Community-acquired pneumonia
Optimising antibiotic policies in the Netherlands, part VIII Revised SWAB Guidelines for antimicrobial therapy of Community-acquired pneumonia Dutch Working Party on Antibiotic Policy (SWAB), April 2005
More informationMore than 4 million episodes of communityacquired
Overview of Recent Guidelines for the Management of Community-Acquired Pneumonia David C. Rhew, MD More than 4 million episodes of communityacquired pneumonia (CAP) occur each year in the United States,
More informationPneumonia Antibiotic Guidance for Adults PAGL Inclusion Approved at January 2017 PGC
Pneumonia Antibiotic Guidance for Adults PAGL Inclusion Approved at January 2017 PGC APPROVED BY: Policy and Guidelines Committee TRUST REFERENCE: B9/2009 AWP Ref: AWP61 Date (approved): July 2008 REVIEW
More informationMarc Decramer 3. Respiratory Division, University Hospitals Leuven, Leuven, Belgium
AAC Accepts, published online ahead of print on April 0 Antimicrob. Agents Chemother. doi:./aac.0001- Copyright 0, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights Reserved.
More informationESCMID Online Lecture Library. by author
Treatment of community-acquired meningitis including difficult to treat organisms like penicillinresistant pneumococci and guidelines (ID perspective) Stefan Zimmerli, MD Institute for Infectious Diseases
More informationCommunity-Acquired Pneumonia. Lisa G. Winston, MD University of California, San Francisco San Francisco General Hospital. Nothing to disclose.
Community-Acquired Pneumonia Lisa G. Winston, MD University of California, San Francisco San Francisco General Hospital Nothing to disclose. Community-Acquired Pneumonia Talk will focus on adults Guideline
More informationCommunity-Acquired Pneumonia (CAP)
Community-Acquired Pneumonia (CAP) Infectious Diseases Advisory Board 14/01/2000 - Woluwé St Lambert Colloquium Longartsen - 11/02/2000 Dr Yvan Valcke Belgian guidelines on the initial diagnostic and therapeutic
More informationObjectives 4/26/2017. Co-Investigators Sadie Giuliani, PharmD, BCPS Claude Tonnerre, MD Jayme Hartzell, PharmD, MS, BCPS
IMPLEMENTATION AND ASSESSMENT OF A GUIDELINE-BASED TREATMENT ALGORITHM FOR COMMUNITY-ACQUIRED PNEUMONIA (CAP) Lucas Schonsberg, PharmD PGY-1 Pharmacy Practice Resident Providence St. Patrick Hospital Missoula,
More informationInfectious Disease 101: Helping the Consultant Pharmacist with Stewardship Principles
Infectious Disease 101: Helping the Consultant Pharmacist with Stewardship Principles Conflicts of Interest None at this time May be discussing off-label indications KALIN M. CLIFFORD, PHARM.D., BCPS,
More informationNQF-ENDORSED VOLUNTARY CONSENSUS STANDARDS FOR HOSPITAL CARE. Measure Information Form Collected For: CMS Voluntary Only
Last Updated: Version 4.4a NQF-ENDORSED VOLUNTARY CONSENSUS STANDARDS FOR HOSPITAL CARE Measure Set: Pneumonia (PN) Performance Measure Identifier: Measure Information Form Collected For: CMS Voluntary
More informationUnderstanding the Hospital Antibiogram
Understanding the Hospital Antibiogram Sharon Erdman, PharmD Clinical Professor Purdue University College of Pharmacy Infectious Diseases Clinical Pharmacist Eskenazi Health 5 Understanding the Hospital
More informationDoxycycline for strep pneumonia
Doxycycline for strep pneumonia Antibiotic Levofloxacin (Levaquin) 750 mg, 500 mg for the treatment of respiratory, skin, and urinary tract infections, user reviews and ratings. 14-12-1995 John G. Bartlett,
More informationPrinciples of Infectious Disease. Dr. Ezra Levy CSUHS PA Program
Principles of Infectious Disease Dr. Ezra Levy CSUHS PA Program I. Microbiology (1) morphology (e.g., cocci, bacilli) (2) growth characteristics (e.g., aerobic vs anaerobic) (3) other qualities (e.g.,
More information4/3/2017 CLINICAL PEARLS: UPDATES IN THE MANAGEMENT OF NOSOCOMIAL PNEUMONIA DISCLOSURE LEARNING OBJECTIVES
CLINICAL PEARLS: UPDATES IN THE MANAGEMENT OF NOSOCOMIAL PNEUMONIA BILLIE BARTEL, PHARMD, BCCCP APRIL 7 TH, 2017 DISCLOSURE I have had no financial relationship over the past 12 months with any commercial
More informationmoxifloxacin intravenous, 400mg/250mL, solution for infusion (Avelox ) SMC No. (650/10) Bayer Schering
moxifloxacin intravenous, 400mg/250mL, solution for infusion (Avelox ) SMC No. (650/10) Bayer Schering 05 November 2010 The Scottish Medicines Consortium (SMC) has completed its assessment of the above
More informationLet me clear my throat: empiric antibiotics in
Let me clear my throat: empiric antibiotics in respiratory tract infections Alexander John Langley, MD MS MPH Goals of this talk Overuse of antibiotics is a major issue, as a result many specialist medical
More information21 st Expert Committee on Selection and Use of Essential Medicines Peer Review Report Antibiotics Review
(1) Have all important studies/evidence of which you are aware been included in the application? Yes No Please provide brief comments on any relevant studies that have not been included: (2) For each of
More informationPharmacokinetics. Absorption of doxycycline is not significantly affected by milk or food, but coadministration of antacids or mineral supplements
Pharmacokinetics. Absorption of doxycycline is not significantly affected by milk or food, but coadministration of antacids or mineral supplements should be avoided. PDR Drug Summaries are concise point-of-care
More informationRoutine internal quality control as recommended by EUCAST Version 3.1, valid from
Routine internal quality control as recommended by EUCAST Version.1, valid from 01-01-01 Escherichia coli Pseudomonas aeruginosa Staphylococcus aureus Enterococcus faecalis Streptococcus pneumoniae Haemophilus
More informationChildrens Hospital Antibiogram for 2012 (Based on data from 2011)
Childrens Hospital Antibiogram for 2012 (Based on data from 2011) Prepared by: Department of Clinical Microbiology, Health Sciences Centre For further information contact: Andrew Walkty, MD, FRCPC Medical
More informationGuidelines for Empiric Antimicrobial Prescribing in Community-Acquired Pneumonia*
special reports Guidelines for Empiric Antimicrobial Prescribing in Community-Acquired Pneumonia* Thomas M. File, Jr, MD, FCCP; Javier Garau, MD; Francesco Blasi, MD, PhD; Christian Chidiac, MD; Keith
More informationAppropriate Management of Common Pediatric Infections. Blaise L. Congeni M.D. Akron Children s Hospital Division of Pediatric Infectious Diseases
Appropriate Management of Common Pediatric Infections Blaise L. Congeni M.D. Akron Children s Hospital Division of Pediatric Infectious Diseases It s all about the microorganism The common pathogens Viruses
More informationEuropean Committee on Antimicrobial Susceptibility Testing
European Committee on Antimicrobial Susceptibility Testing Routine and extended internal quality control as recommended by EUCAST Version 5.0, valid from 015-01-09 This document should be cited as "The
More informationInteractive session: adapting to antibiogram. Thong Phe Heng Vengchhun Felix Leclerc Erika Vlieghe
Interactive session: adapting to antibiogram Thong Phe Heng Vengchhun Felix Leclerc Erika Vlieghe Case 1 63 y old woman Dx: urosepsis? After 2 d: intermediate result: Gram-negative bacilli Empiric antibiotic
More informationSHC Clinical Pathway: HAP/VAP Flowchart
SHC Clinical Pathway: Hospital-Acquired and Ventilator-Associated Pneumonia SHC Clinical Pathway: HAP/VAP Flowchart v.08-29-2017 Diagnosis Hospitalization (HAP) Pneumonia develops 48 hours following: Endotracheal
More informationDeveloping Well-Differentiated Antibiotics. June 2017 Mark Hahn Chief Financial Officer
Developing Well-Differentiated Antibiotics June 2017 Mark Hahn Chief Financial Officer Forward Looking Statements This presentation contains forward-looking statements regarding future events. These statements
More informationUCSF guideline for management of suspected hospital-acquired or ventilatoracquired pneumonia in adult patients
Background/methods: UCSF guideline for management of suspected hospital-acquired or ventilatoracquired pneumonia in adult patients This guideline establishes evidence-based consensus standards for management
More informationMono- versus Bitherapy for Management of HAP/VAP in the ICU
Mono- versus Bitherapy for Management of HAP/VAP in the ICU Jean Chastre, www.reamedpitie.com Conflicts of interest: Consulting or Lecture fees: Nektar-Bayer, Pfizer, Brahms, Sanofi- Aventis, Janssen-Cilag,
More informationMisericordia Community Hospital (MCH) Antimicrobial Stewardship Report. July December 2013 Second and Third Quarters 2014
H e a l i n g t h e B o d y E n r i c h i n g t h e M i n d N u r t u r i n g t h e S o u l Misericordia Community Hospital (MCH) Antimicrobial Stewardship Report July December 213 Second and Third Quarters
More informationEinheit für pädiatrische Infektiologie Antibiotics - what, why, when and how?
Einheit für pädiatrische Infektiologie Antibiotics - what, why, when and how? Andrea Duppenthaler andrea.duppenthaler@insel.ch Limping patient local pain swelling tenderness warmth fever acute Osteomyelitis
More informationThese recommendations were approved for use by the Pharmaceutical and Therapeutics Committee, RCWMCH on 1 February 2017.
Antibiotic regimens for suspected hospital-acquired infection (HAI) outside the Paediatric Intensive Care Unit at Red Cross War Memorial Children s Hospital (RCWMCH) Lead author: Brian Eley Contributing
More informationAntibacterial Resistance: Research Efforts. Henry F. Chambers, MD Professor of Medicine University of California San Francisco
Antibacterial Resistance: Research Efforts Henry F. Chambers, MD Professor of Medicine University of California San Francisco Resistance Resistance Dose-Response Curve Antibiotic Exposure Anti-Resistance
More informationAnnual Report: Table 1. Antimicrobial Susceptibility Results for 2,488 Isolates of S. pneumoniae Collected Nationally, 2005 MIC (µg/ml)
Streptococcus pneumoniae Annual Report: 5 In 5, a total of, isolates of pneumococci were collected from 59 clinical microbiology laboratories across Canada. Of these, 733 (9.5%) were isolated from blood
More informationCombination vs Monotherapy for Gram Negative Septic Shock
Combination vs Monotherapy for Gram Negative Septic Shock Critical Care Canada Forum November 8, 2018 Michael Klompas MD, MPH, FIDSA, FSHEA Professor, Harvard Medical School Hospital Epidemiologist, Brigham
More informationGrey Nuns Community Hospital (GNCH) Antimicrobial Stewardship July December 2017
Grey Nuns Community Hospital (GNCH) Antimicrobial Stewardship July December 217 Table of Contents Table of Contents... 2 I. Executive Summary... 3 II. GNCH Total Antimicrobial Utilization... 4 III. GNCH
More informationShould we test Clostridium difficile for antimicrobial resistance? by author
Should we test Clostridium difficile for antimicrobial resistance? Paola Mastrantonio Department of Infectious Diseases Istituto Superiore di Sanità, Rome,Italy Clostridium difficile infection (CDI) (first
More informationIMPLEMENTATION AND ASSESSMENT OF A GUIDELINE-BASED TREATMENT ALGORITHM FOR COMMUNITY-ACQUIRED PNEUMONIA (CAP)
IMPLEMENTATION AND ASSESSMENT OF A GUIDELINE-BASED TREATMENT ALGORITHM FOR COMMUNITY-ACQUIRED PNEUMONIA (CAP) Lucas Schonsberg, PharmD PGY-1 Pharmacy Practice Resident Providence St. Patrick Hospital Missoula,
More informationAntimicrobial Stewardship in Ambulatory Care
Antimicrobial Stewardship in Ambulatory Care Nila Suntharam, M.D. May 5, 2017 Dr. Suntharam indicated no potential conflict of interest to this presentation. She does not intend to discuss any unapproved/investigative
More informationAntimicrobial Stewardship Program: Local Experience
Antimicrobial Stewardship Program: Local Experience Dr. WU Tak Chiu Associate Consultant Division of Infectious Diseases Department of Medicine Queen Elizabeth Hospital 18th January 2011 QUEEN ELIZABETH
More informationACUTE EXACERBATIONS of COPD (AE-COPD) : The Belgian perspective
ACUTE EXACERBATIONS of COPD (AE-COPD) : The Belgian perspective Antwerpen 8 november 2002 Yvan Valcke MD PhD AZ Maria Middelares Sint-Niklaas ACUTE EXACERBATIONS of COPD (AE-COPD) Treatment of AECB Role
More informationORIGINAL INVESTIGATION. Associations Between Initial Antimicrobial Therapy and Medical Outcomes for Hospitalized Elderly Patients With Pneumonia
ORIGINAL INVESTIGATION Associations Between Initial Antimicrobial Therapy and Medical Outcomes for Hospitalized Elderly Patients With Pneumonia Patrick P. Gleason, PharmD; Thomas P. Meehan, MD, MPH; Jonathan
More informationThe International Collaborative Conference in Clinical Microbiology & Infectious Diseases
The International Collaborative Conference in Clinical Microbiology & Infectious Diseases PLUS: Antimicrobial stewardship in hospitals: Improving outcomes through better education and implementation of
More informationStreptococcus pneumoniae. Oxacillin 1 µg as screen for beta-lactam resistance
Streptococcus pneumoniae Oxacillin µg as screen for beta-lactam resistance Version 6. June Streptococcus pneumoniae and zone diameter correlates The following histograms present inhibition zone diameter
More informationAntimicrobial Susceptibility Patterns
Antimicrobial Susceptibility Patterns KNH SURGERY Department Masika M.M. Department of Medical Microbiology, UoN Medicines & Therapeutics Committee, KNH Outline Methodology Overall KNH data Surgery department
More information2017 SURVEILLANCE OF SURGICAL SITES INFECTIONS FOLLOWING TOTAL HIP AND KNEE ARTHROPLASTY
Canadian Nosocomial Infection Surveillance Program 2017 SURVEILLANCE OF SURGICAL SITES INFECTIONS FOLLOWING TOTAL HIP AND KNEE ARTHROPLASTY FINAL Working Group: E. Henderson, M. John, I. Davis, S. Dunford,
More informationAntimicrobial Susceptibility Testing: Advanced Course
Antimicrobial Susceptibility Testing: Advanced Course Cascade Reporting Cascade Reporting I. Selecting Antimicrobial Agents for Testing and Reporting Selection of the most appropriate antimicrobials to
More informationSt. Joseph s General Hospital Vegreville. and. Mary Immaculate Care Centre. Antimicrobial Stewardship Report
St. Joseph s General Hospital Vegreville and Mary Immaculate Care Centre Antimicrobial Stewardship Report January to June 217 Introduction Antibiotics are among the most commonly prescribed medications
More informationAntimicrobial stewardship in managing septic patients
Antimicrobial stewardship in managing septic patients November 11, 2017 Samuel L. Aitken, PharmD, BCPS (AQ-ID) Clinical Pharmacy Specialist, Infectious Diseases slaitken@mdanderson.org Conflict of interest
More informationPrescribing Guidelines for Outpatient Antimicrobials in Otherwise Healthy Children
Prescribing Guidelines for Outpatient Antimicrobials in Otherwise Healthy Children Prescribing Antimicrobials for Common Illnesses When treating common illnesses such as ear infections and strep throat,
More informationWhat s new in EUCAST methods?
What s new in EUCAST methods? Derek Brown EUCAST Scientific Secretary Interactive question 1 MIC determination MH-F broth for broth microdilution testing of fastidious microorganisms Gradient MIC tests
More informationSafety of an Out-Patient Intravenous Antibiotics Programme
Safety of an Out-Patient Intravenous Antibiotics Programme Chan VL, Tang ESK, Leung WS, Wong L, Cheung PS, Chu CM Department of Medicine & Geriatrics United Christian Hospital Outpatient Parental Antimicrobial
More informationAntibiotic Therapy for Adults Hospitalized With Community-Acquired Pneumonia A Systematic Review
Clinical Review & Education Review Antibiotic Therapy for Adults Hospitalized With Community-Acquired Pneumonia A Systematic Review Jonathan S. Lee, MD; Daniel L. Giesler, MD, PharmD; Walid F. Gellad,
More informationDuke University Hospital Guideline for Empiric Inpatient Treatment of Cancer- Related Neutropenic Fever in Adult Patients
Duke University Hospital Guideline for Empiric Inpatient Treatment of Cancer- Related Neutropenic Fever in Adult Patients PURPOSE Fever among neutropenic patients is common and a significant cause of morbidity
More informationPerichondritis: Source: UpToDate Ciprofloxacin 10 mg/kg/dose PO (max 500 mg/dose) BID Inpatient: Ceftazidime 50 mg/kg/dose q8 hours IV
Empiric Antibiotics for Pediatric Infections Seen in ED NOTE: Choice of empiric antibiotic therapy must take into account local pathogen frequency and resistance patterns, individual patient characteristics,
More informationAntimicrobial Pharmacodynamics
Antimicrobial Pharmacodynamics November 28, 2007 George P. Allen, Pharm.D. Assistant Professor, Pharmacy Practice OSU College of Pharmacy at OHSU Objectives Become familiar with PD parameters what they
More informationDisclosures. Antimicrobials for Respiratory Tract Infections. What is the treatment of choice for ABRS? Acute Bacterial Rhinosinusitis
Antimicrobials for Respiratory Tract Infections B. Joseph Guglielmo, Pharm.D. Professor and Dean School of Pharmacy University of California San Francisco Disclosures No disclosures regarding conflict
More informationAntimicrobial Stewardship Strategy: Antibiograms
Antimicrobial Stewardship Strategy: Antibiograms A summary of the cumulative susceptibility of bacterial isolates to formulary antibiotics in a given institution or region. Its main functions are to guide
More informationWhat is pneumonia? Infection of the lung parenchyma Causative agents include bacteria, viruses, fungi, protozoa.
Pneumonia What is pneumonia? Infection of the lung parenchyma Causative agents include bacteria, viruses, fungi, protozoa www.netmedicine.com/xray/xr.htm Definition acute infectious disease, etiology usually
More informationORIGINAL ARTICLE. Focus Technologies, Inc., 1 Hilversum, The Netherlands, 2 Herndon, Virginia and 3 Franklin, Tennessee, USA
ORIGINAL ARTICLE In vitro susceptibility of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis: a European multicenter study during 2000 2001 M. E. Jones 1, R. S. Blosser-Middleton
More informationEuropean Committee on Antimicrobial Susceptibility Testing
European Committee on Antimicrobial Susceptibility Testing Routine and extended internal quality control for MIC determination and disk diffusion as recommended by EUCAST Version 8.0, valid from 018-01-01
More informationUpdate on Resistance and Epidemiology of Nosocomial Respiratory Pathogens in Asia. Po-Ren Hsueh. National Taiwan University Hospital
Update on Resistance and Epidemiology of Nosocomial Respiratory Pathogens in Asia Po-Ren Hsueh National Taiwan University Hospital Ventilator-associated Pneumonia Microbiological Report Sputum from a
More informationApproach to pediatric Antibiotics
Approach to pediatric Antibiotics Gassem Gohal FAAP FRCPC Assistant professor of Pediatrics objectives To be familiar with common pediatric antibiotics o Classification o Action o Adverse effect To discus
More informationEARS Net Report, Quarter
EARS Net Report, Quarter 4 213 March 214 Key Points for 213* Escherichia coli: The proportion of patients with invasive infections caused by E. coli producing extended spectrum β lactamases (ESBLs) increased
More informationFluoroquinolones in 2007: the Angels, the Devils, and What Should the Clinician Do?
Fluoroquinolones in 2007: the Angels, the Devils, and What Should the Clinician Do? David C. Hooper, M.D. Division of Infectious Diseases Infection Control Unit Massachusetts General Hospital Harvard Medical
More informationAntibiotic Usage Guidelines in Hospital
SUPPLEMENT TO JAPI december VOL. 58 51 Antibiotic Usage Guidelines in Hospital Camilla Rodrigues * Use of surveillance data information of Hospital antibiotic policy guidelines from Hinduja Hospital. The
More informationENTEROCOCCI. April Abbott Deaconess Health System Evansville, IN
ENTEROCOCCI April Abbott Deaconess Health System Evansville, IN OBJECTIVES Discuss basic antimicrobial susceptibility principles and resistance mechanisms for Enterococcus Describe issues surrounding AST
More informationPRACTIC GUIDELINES for APPROPRIATE ANTIBIOTICS USE
PRACTIC GUIDELINES for APPROPRIATE ANTIBIOTICS USE Global Alliance for Infection in Surgery World Society of Emergency Surgery (WSES) and not only!! Aims - 1 Rationalize the risk of antibiotics overuse
More information